Progressive phases of multiple sclerosis are associated with inhibited differentiation of the progenitor cell population that generates the mature oligodendrocytes required for remyelination and disease remission. To identify selective inducers of oligodendrocyte differentiation, we performed an image-based screen for myelin basic protein (MBP) expression using primary rat optic-nerve-derived progenitor cells. Here we show that among the most effective compounds identifed was benztropine, which significantly decreases clinical severity in the experimental autoimmune encephalomyelitis (EAE) model of relapsing-remitting multiple sclerosis when administered alone or in combination with approved immunosuppressive treatments for multiple sclerosis. Evidence from a cuprizone-induced model of demyelination, in vitro and in vivo T-cell assays and EAE adoptive transfer experiments indicated that the observed efficacy of this drug results directly from an enhancement of remyelination rather than immune suppression. Pharmacological studies indicate that benztropine functions by a mechanism that involves direct antagonism of M1 and/or M3 muscarinic receptors. These studies should facilitate the development of effective new therapies for the treatment of multiple sclerosis that complement established immunosuppressive approaches.
.
Despite some controversy regarding their intrinsic in vitro and in vivo lineage potential [2] [3] [4] , compelling evidence indicates that a widespread proliferating population of nerve and glial antigen-2 (NG2), plateletderived growth factor receptor alpha (PDGFR-a) positive cells, termed NG2-glia or oligodendrocyte precursor cells (OPCs), are the major source of newly formed mature oligodendrocytes required for remyelination [5] [6] [7] . Remission in multiple sclerosis is largely dependent on migration of OPCs to sites of injury and subsequent differentiation to mature cells capable of repair 1, 2, 8 . Studies evaluating the presence and relative densities of OPCs at sites of chronically demyelinated multiple sclerosis lesions indicate that it is not a failure of repopulation or migration of OPCs, but rather inhibition of OPC differentiation at sites of injury that contributes to disease progression [9] [10] [11] [12] . As such, the identification of small molecules that selectively induce differentiation of OPCs at sites of demyelinated lesions and thereby enhance remyelination would have a considerable impact on the development of new effective treatments for multiple sclerosis 13 .
High-throughput OPC differentiation screen
To identify drug-like small molecules that selectively induce OPC differentiation, we developed a high content imaging assay based on the induction of MBP expression in primary rat optic nerve-derived OPCs cultured for 6 days under basal differentiation conditions. Primary rodent OPCs proliferate in vitro when cultured in serum-free media containing PDGF-AA 14 . Upon withdrawal of PDGF-AA, immature A2B5
1 OPCs cease to proliferate, but also fail to efficiently differentiate into MBP producing mature oligodendrocytes. Addition of thyroid hormone (triiodothyronine; T3), a known inducer of OPC differentiation [15] [16] [17] [18] [19] , at the time of mitogen withdrawal results in the differentiation of OPCs to MBP-positive oligodendrocytes after 6 days of culture (Extended Data Fig. 1a ). However, T3 has several physiological effects that make it unattractive as a therapeutic agent for multiple sclerosis. This assay was adapted to a high-throughput format and used to screen a collection of ,100,000 structurally diverse molecules (Extended Data Fig. 1b) . This led to the identification of several previously identified inducers of OPC differentiation [19] [20] [21] [22] [23] (Extended Data Fig. 1c , summarized in Supplementary Table 1 ). Unfortunately, these molecules have limited therapeutic potential due to off-target activities, toxicity, poor brain exposure and/or demonstrated lack of in vivo efficacy. Among the most effective inducers of OPC differentiation was benztropine (half-maximum effective concentration (EC 50 ) ,500 nM) ( Fig. 1a and Extended Data Fig. 2a, b) , which we chose to investigate further because it is an orally available approved drug that readily crosses the blood-brain barrier.
Benztropine-induced in vitro differentiation of rodent OPCs was confirmed by evaluating the transcription and translation levels of the oligodendrocyte-specific markers MBP and myelin oligodendroglial glycoprotein (MOG) by western blot and quantitative polymerase chain reaction with reverse transcription (qRT-PCR) analysis (Extended Data Fig. 2c, d ). Additionally, in vitro OPC differentiation activity was confirmed by immunofluorescence analysis using multiple markers specifically expressed in mature oligodendrocytes following 6 days of compound treatment (Extended Data Fig. 2e ). Furthermore, transcript levels of cyclin D1, cyclin D2, c-Fos and c-Jun were significantly decreased in benztropine-treated OPCs, consistent with general inhibition of cell cycle progression (Extended Data Fig. 2f ). To determine the stage of OPC differentiation at which benztropine is active 24, 25 , we treated OPCs for differing durations starting at several time points (Extended Data Fig. 2g, h ). Maximal induction of MBP expression was observed when the compound was added within 48 h of PDGF-AA withdrawal and cells were further cultured for at least 5 days, indicating that this drug probably acts on immature A2B5
1 OPCs and not the intermediate 'pre-oligodendrocyte' stage of differentiation.
Benztropine was also found to induce robust differentiation of rat and mouse OPCs when co-cultured with mouse embryonic-stem-cellderived neurons 26 or mouse cortex-derived cells 27 ( Fig. 1b and Extended Data Fig. 3a , b, respectively). We also quantified the effect of benztropine on the in vitro myelination of axons by quantifying the co-localization of MBP positive oligodendrocyte processes and axons (Extended Data  Fig. 3c) . The results showed a significant increase in the absolute amount of myelination in benztropine-treated co-cultures (Fig. 1c, d ). This increase could result from enhanced maturation of oligodendrocytes and/or may reflect elevated myelination capacity of mature oligodendrocytes. To evaluate these two possibilities, we normalized the absolute amount of myelin to the total number of oligodendrocytes. Benztropine treated cultures had a significantly higher percentage of myelinating oligodendrocytes (Extended Data Fig. 3d ), which indicates that benztropine not only enhances maturation of oligodendrocytes, but also promotes myelination.
M1/M3 muscarinic receptor antagonism
Benztropine is used clinically for the management of Parkinson's disease and its pharmacological effects are thought to result from its anticholinergic activity 28 . However, benztropine is also a centrally acting anti-histamine 29 and dopamine re-uptake inhibitor 30 . To determine which, if any, of these activities play a role in OPC differentiation, we evaluated the ability of selective agonists of muscarinic acetylcholine receptors (mAChRs) or nicotinic acetylcholine receptors (the agonists carbachol or nicotine, respectively) to block benztropine activity. Inhibition of benztropine-induced OPC differentiation was observed in the presence of carbachol (Extended Data Fig. 3e, f) , whereas nicotine had no effect on OPC differentiation (Extended Data Fig. 3g ). The dopamine receptor antagonist haloperidol, the dopamine receptor agonist quinpirole and the histaminergic receptor agonists histamine and histamine trifloromethyl-toluidine (HTMT) had no effect on benztropine-induced OPC differentiation (Extended Data Fig. 3h-k) . Moreover, neither quinpirole nor nicotinic receptor antagonists (for example, tubocuraine, mivacurium, mecamylamine, pancuronium, atracurium or trimethophan) induced significant OPC differentiation (Extended Data Fig. 3l ). We then evaluated a panel of mAChR antagonists (atropine, oxybutynin, scopolamine, ipratropium and propiverine) and found that all induced OPC differentiation in a dose-dependent manner with differing potencies (Supplementary Table 2) , consistent with a mechanism of action that is dependent on muscarinic receptor antagonism.
To examine further the role of muscarinic receptor antagonism in benztropine-induced OPC differentiation and determine if a more potent and/or clinically useful drug could be identified, we evaluated a broader panel of structurally diverse muscarinic receptor antagonists. Of the 42 compounds tested, 20, which cluster amongst 4 related structural classes, were found to be active (Supplementary Tables 2  and 3 ). However, none were found to be more potent than benztropine. The ability of muscarinic receptor agonists to inhibit benztropineinduced OPC differentiation provides strong evidence that muscarinic receptor antagonism is an essential component of the mechanism of action. The inactivity of several of the muscarinic antagonists we evaluated could be the result of off-target inhibitory activities or toxicityrelated effects. We cannot rule out the possibility that an additional biological activity, common among the active muscarinic receptor antagonists identified, is required for OPC differentiation. However, consistent with the proposed mechanism, it has recently been demonstrated that muscarinic activation causes decreased expression of myelin proteins in mature oligodendrocytes and modulates the expression of known regulators of differentiation (for example, PDFGRa) in immature OPCs
31
. Furthermore, Notch1 is a known negative regulator of OPC differentiation 32, 33 and, consistent with the observation that muscarinic receptor activation causes increased expression of Notch1 (ref. 31), we found that treatment of OPCs with benztropine results in a significant decrease in Notch1 expression in immature OPCs (Extended Data Fig. 3m ).
OPCs are known to express mAChRs, predominantly subtypes M1, M3 and M5 (ref. 34). We confirmed expression of these receptors, as well as that of the acetylcholine-synthesizing enzyme choline acetyl transferase (ChAT), by qRT-PCR (Extended Data Fig. 3n, o) . Activation of mAChRs triggers protein-kinase-C-dependent activation of the MAPK/ERK pathway leading to modulation of c-Fos expression 35 . Western blot analysis of benztropine-treated OPCs is consistent with general inhibition of this pathway (decreased phospho-Akt and stimulated phosphorylation of p38 MAPK and CREB) (Extended Data  Fig. 3p ). Activation of M1 and M3 mAChRs is coupled to downstream signalling events through phospholipase C, which results in increased intracellular calcium concentrations 35 , whereas M2 and M4 mAChR 
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activation inhibits adenylate cyclase, leading to decreased intracellular cAMP levels 31 . In OPCs, benztropine and the muscarinic antagonist atropine both inhibited carbachol-induced calcium influx (Extended Data Fig. 3q ), but had no effect on cAMP levels (Extended Data Fig. 3r ). Together, these results suggest that benztropine induces OPC differentiation by a mechanism involving direct antagonism of M1/M3 muscarinic receptors. Acetylcholine is a known regulator of OPC proliferation and, as such, muscarinic receptor subtypes represent a promising class of therapeutic targets for the modulation of OPC proliferation and differentiation [31] [32] [33] [34] [35] .
Efficacy in the PLP-induced EAE model
We next examined the activity of benztropine in the proteolipid protein (PLP)-induced EAE rodent model of relapsing-remitting multiple sclerosis 36, 37 . Despite some inherent limitations of this model, all therapies approved for the treatment of MS decrease the clinical severity of EAE 38, 39 . This model is most commonly used to evaluate the potential efficacy of immunosuppressive agents, but can also be used to determine the effectiveness of promyelinating agents that function by enhancing OPC differentiation 40, 41 . Benztropine (10 mg per kg) was administered prophylactically by a daily intraperitoneal (i.p.) injection regimen initiated at the onset of PLP immunization. Benztropine dramatically decreased the severity of the acute phase of disease and virtually eliminated the relapse phase compared to vehicle-treated controls ( Fig. 2a and Extended Data Fig. 4a ). We next evaluated efficacy when the drug was administered therapeutically, by starting daily injections at the first sign of disease. Treatment with benztropine in this mode again led to functional recovery; significant decreases in clinical severity during remission phases were observed and the occurrence of relapse was again virtually eliminated (Fig. 2a) . In fact, treatment with benztropine in this mode resulted in decreased clinical severity comparable to, or better than, that observed for the immunosuppressive multiple sclerosis drugs FTY720 or interferon-b (administered at reported therapeutic doses in mice) (Fig. 2a) .
In parallel experiments, when benztropine was dosed in a prophylactic mode, we isolated spinal cords from drug-or vehicle-treated mice at various time points before the onset of symptoms and during the acute and relapse phases of disease. Sections from many regions were stained with Luxol fast blue to visualize myelin or Luxol fast blue and hematoxylin and eosin (H&E) to visualize both myelin and infiltrating immune cells. Immunohistochemical analysis was also performed using antibodies that recognize markers of mature oligodendrocytes (MBP and glutathione S-transferase; GST-p), immature OPCs (NG2) or infiltrating immune cells (CD45). During acute and relapse phases of disease, sections from both vehicle-and benztropine-treated mice showed significant infiltration by H&E-and CD45-positive immune cells (Extended Data Fig. 4b-d) . In vehicle-treated mice, infiltration corresponded to areas of significant demyelination (Extended Data Fig. 4b, e) . In contrast, in benztropine-treated mice, a large number of immune-cell-infiltrated areas stained positive for Luxol fast blue or MBP, a finding consistent with a regenerative versus immunosuppressive mechanism (Extended Data Fig. 4b, e) . We further evaluated drugenhanced remyelination using confocal microscopy (Fig. 2b) . Quantitative image analysis of many random fields per group indicated that benztropine treatment caused a significant increase in the number of GST-p 1 mature oligodendrocytes from ,500 to ,1,100 per field compared to vehicle ( Fig. 2c and Extended Data Fig. 4d ). The observed increase in mature oligodendrocyte numbers is consistent with a mechanism of benztropine-induced clinical recovery that involves the stimulation of OPC differentiation, leading to enhanced remyelination, in the context of an inflammatory environment. Notably, at time points before any observable immune cell infiltration or disease onset (day 8), a similar (,twofold) increase in the number of mature oligodendrocyte was observed in the spinal cords of benztropinetreated mice (Extended Data Fig. 4c, d ). This observation is consistent with the time frame of in vitro activity. Furthermore, it is consistent with the occurrence of benztropine-induced OPC differentiation in vivo in the absence of inflammatory insult and provides an explanation for the substantial decrease in clinical severity observed during the acute phase of disease when the drug is dosed in a prophylactic mode. Mature oligodendrocytes capable of remyelination are poised for repair (or possibly protection) before immunological attack. Importantly, general toxicity was not observed either microscopically or macroscopically in drugtreated mice following 4 weeks of daily injections at 10 mg per kg.
Electron microscopy was used to observe myelin surrounding spinal cord axons in benztropine-and vehicle-treated mice during the peak of the acute phase of disease. Immune-cell-infiltrated areas of spinal cords from vehicle-treated mice exhibited characteristic oligodendrogliopathy along with damaged axons with loose and separated layers of myelin sheaths 42 (Fig. 3a, b and Extended Data Fig. 4f ). Benztropine treatment did not influence the infiltration or relative abundance of encephalogenic T cells and other inflammatory immune effector cells, nor did it affect the ability of these cells to cause demyelination during the acute phase of disease. Evidence for demyelination at this time point is provided by the significant (P , 0.01) increases in observed g-ratios (ratio of axon diameter to myelinated axon diameter) for both drugand vehicle-treated mice compared to non-diseased controls ( Fig. 3c and Extended Data Fig. 4g-i) . Drug treatment resulted in extensive remyelination, as evidenced by the presence of abundant newly formed and notably thinner (compared to those of non-diseased mice) myelin sheaths (a characteristic associated with remyelination 5 ) (Fig. 3a, b and 
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Extended Data Fig. 4f ). Specifically, the g-ratios in benztropine-treated mice were significantly lower (P , 0.01) than in vehicle-treated mice, yet still significantly higher (P , 0.01) than in non-diseased mice ( Fig. 3c and Extended Data Fig. 4g -i). Moreover, in these areas, myelin sheaths were observed in different phases of remyelination (axons undergoing initial wrapping, partial remyelination and almost complete remyelination 42 ) ( Fig. 3d and Extended Data Fig. 4j ), strongly supporting a benztropine-induced remyelination effect.
Effect on the immune system of EAE mice
The primary immunological processes involved in multiple sclerosis and EAE are thought to be T-cell mediated. To determine the extent to which the efficacy of benztropine in the EAE model results from T cell inhibitory activity, we evaluated the effects of benztropine and other muscarinic antagonists (atropine, oxybutynin, scopolamine, ipratropium and propiverine) on T-cell activation and proliferation. Notably, it has been reported that muscarinic receptors are expressed on T cells 43 . However, neither benztropine nor the other muscarinic antagonists had an effect on T-cell proliferation in vitro, as measured using a carboxyfluorescein succinimidyl ester (CFSE) labelling assay (Extended Data Fig. 5a ), nor did they affect T-cell activation as determined by assessing CD4
1

CD69
1 and CD4 Fig. 5b , c). We also evaluated the effect of benztropine on the immune system in vivo in SJL/J mice in which EAE had or had not been induced with PLP. In both diseased and healthy animals, benztropine had no effect on the number of splenic naive (CD44 lo ) or activated (CD44 Hi ) CD4
1 and CD8 1 T cells (Extended Data Fig. 5d -f). A minor, but significant, decrease in B cell numbers was observed following treatment with benztropine (Extended Data Fig. 5e , f), and benztropine had no effect on cytokine (IL-2, IL-10, IFN-c, TNF-a) producing T-cell populations isolated from drug-or vehicle-treated normal or diseased mice (Extended Data Fig. 5e , f). We also found that benztropine had no effect on antigen-induced IgG production (Extended Data Fig. 5g ). Next, we analysed the effect of benztropine on in vitro macrophage development and M1/M2 polarization and observed no significant differences between benztropine-treated cultures and controls (Extended Data Fig. 6 ). Additionally, the expression of M1 or M2 polarization markers in spleens, spinal cords, as well as spinal-infiltrating leukocytes isolated from EAE mice treated with benztropine for 14 days, were equivalent to those of controls (Extended Data Fig. 7) .
We next performed the adoptive transfer model of EAE 44 to further demonstrate that benztropine does not affect T-cell development or function. Splenocytes were isolated from SJL/J donor mice, following immunization with PLP and immediate daily injection with benztropine (10 mg per kg) or saline for 10 days, and then cultured in vitro in the presence of benztropine (5 mM) or vehicle, respectively (Extended Data Fig. 8 ). Injection of splenocytes from either donor group resulted in equally severe transfer of EAE disease to recipient mice (Extended Data Fig. 8 : groups 1 and 3), providing evidence that benztropine had no effect on the development and function of PLP-specific T cells in vivo or in vitro. Benztropine (10 mg per kg) treatment of recipient mice, injected with splenocytes from vehicle-or benztropine-treated donor mice, resulted in significant reductions in clinical severity scores (Extended Data Fig. 8 : groups 2 and 4) compared to controls (Extended Data Fig. 8 : groups 1 and 3). Taken together, these results strongly suggest that the observed efficacy of benztropine in the EAE model results from remyelination arising from enhanced oligodendrogenesis rather than immune suppression.
Efficacy of benztropine in the cuprizone model
We further evaluated the ability of benztropine to induce OPC differentiation and enhance remyelination in vivo using the T-cell-independent cuprizone-induced model of demyelination. Inclusion of 0.2% (w/w) cuprizone in the diet of C57BL/6 mice induces a demyelination program that proceeds with a defined series of events over a characteristic time course in which the corpus callosum shows peak demyelination following 6-7 weeks 45 . Spontaneous remyelination is observed 2-4 weeks following cuprizone withdrawal 46 . By administering drugs when a cuprizone-free diet is reintroduced, the efficacy of promyelinating agents can be examined by evaluating the relative kinetics of OPCdependent remyelination 45, 46 . Upon withdrawal of cuprizone, we administered vehicle or benztropine (10 mg per kg) by daily i.p. injections for 5 weeks. During this time, mice were euthanized weekly and the degree of remyelination was quantitatively established by staining the corpus callosum regions of harvested brains with Luxol fast blue and anti-GST-p 1 antibody. Significant demyelination was clearly observed after seven weeks of cuprizone treatment compared to naive animals ( Fig. 4a , top left and bottom left panels). Consistent with enhanced OPC differentiation and accelerated remyelination, overall myelin staining (Fig. 4a , middle and right panels; 4b; Extended Data Fig. 9 ) and the number of GST-p 1 mature oligodendrocytes (Fig. 4c, d ) increased significantly in the corpus callosum at week 2 following benztropine treatment compared to the spontaneous remyelination observed in vehicle controls. As expected, at later time points, spontaneous remyelination was relatively complete and no significant differences between drug-and vehicle-treated animals were observed. A lack of difference at these later time points indicates that, even after five weeks of treatment, benztropine is not toxic to mature oligodendrocytes. These data again indicate that benztropine enhances the process of in vivo remyelination by directly inducing OPC differentiation.
Benztropine is dose-sparing with FTY720
For the treatment of multiple sclerosis, an OPC differentiation-inducing drug would most probably be introduced clinically as part of a combination therapy with an immunosuppressive drug. Using the PLPinduced EAE model, we therefore evaluated the clinical efficacy of benztropine when combined with either of two immunosuppressive drugs approved for the treatment of multiple sclerosis, interferon-b , whereas the latter is an S1P agonist that blocks T-cell trafficking 50 . Initially, all three drugs were dosed individually over a range of concentrations to determine suboptimal and maximal effective/tolerated doses in the EAE model (Extended Data  Figs 4a and 10a, b) . Addition of 2.5 mg per kg of benztropine (suboptimal dose) to reported therapeutic doses of FTY720 (1 mg per kg) (Extended Data Fig. 10c ) or interferon-b (10,000 U per mouse) (Extended Data Fig. 10d ) resulted in decreased clinical severity comparable to, or greater than, either FTY720 or interferon-b alone. Furthermore, the combination of a suboptimal dose of benztropine (2.5 mg per kg) with a suboptimal dose of FTY720 (0.1 mg per kg) resulted in a significant decrease in clinical severity (Extended Data Fig. 10e ) comparable to the clinical efficacy observed when FTY720 was given alone at the reported therapeutically effective dose of 1 mg per kg (Extended Data Fig. 10f ). Addition of benztropine to FTY720 does not result in a decrease in immune cell infiltration compared to FTY720 treatment alone (Extended Data Fig. 10g, h ), and addition of FTY720 to benztropine does not result in an increase in the number of oligodendrocytes compared to benztropine treatment alone (Extended Data Fig. 10i, j) . This finding indicates that the observed benefit (Extended Data Fig. 10k ) that results from this drug combination is derived from an additive effect that occurs when both immunological and remyelination mechanisms are targeted simultaneously. This observation may prove clinically relevant, because FTY720 treatment is associated with a dose-dependent bradycardia, which might be reduced by combination therapy with benztropine, and benztropine is associated with dose-dependent adverse neurological side effects.
Discussion
We have identified a centrally acting drug that, when administered in a clinically relevant model of multiple sclerosis, significantly decreases disease severity by directly stimulating the differentiation of a progenitor cell population leading to enhanced remyelination and functional recovery. Pharmacological data clearly indicates that the mechanism of action of benztropine is dependent on muscarinic receptor antagonism, but not any of its other known biological activities. However, based on the lack of activity of some of the anti-muscarinics tested, we cannot rule out the possibility that an additional unidentified target may exist that is common to all of the active anti-muscarinics identified. Further, although experimental evidence clearly indicates that benztropine induces OPC differentiation and remyelination in vitro and in vivo, it is possible that the therapeutic effect observed in the EAE model could also result in part from a protective effect derived from increased glial cell density. Inclusion of benztropine in EAE treatment regimens involving existing approved immunosuppressive drugs results in enhanced functional recovery and, in the case of FTY720, significantly decreases the dosages of both drugs that are required to achieve equivalent efficacy. Successful translation of these findings to multiple sclerosis patient populations will require further preclinical and clinical evaluation, as benztropine and other anti-muscarinics have significant dose-dependent neurological and psychiatric side effects. To our knowledge, these results provide the first in vivo evidence supporting the notion that benefit can be achieved by treating multiple-sclerosis-like symptoms using the combination of an immunosuppressive drug with a remyelination enhancer and may have a significant effect on the development of new and more effective therapies for the treatment of multiple sclerosis. Finally, we are evaluating other hits from our screen to identify compounds that induce remyelination by mechanisms distinct from that of benztropine.
METHODS SUMMARY
Cell culture and high-throughput screening. Primary rat optic nerve-derived OPCs were screened in 384-well format (1.5 mM compound) using basal differentiation conditions. Following immunostaining using an MBP-specific antibody, plates were imaged and analysed using Opera (Perkin Elmer) or Cell Insight (Thermo) high content imaging systems.
In vivo animal models. The PLP-induced EAE model was performed and scored using 8-week-old female SJL/J mice as described 37 . Mice received daily i.p. injections with vehicle or drug using either prophylactic or therapeutic regimens. For the cuprizone model, C57BL/6 mice were fed 0.2% w/w cuprizone with chow for 7 weeks and thereafter with normal chow, at which point benztropine (10 mg per kg) or saline was injected daily (i.p.) starting for 5 weeks. Spinal cords were isolated and histological analysis was performed at weeks 0-5 following cuprizone withdrawal.
Online Content Any additional Methods, Extended Data display items and Source Data are available in the online version of the paper; references unique to these sections appear only in the online paper. )-coated flasks in OPC proliferation media (Neurobasal Media, Invitrogen) supplemented with B27-without vitamin A (Invitrogen), non-essential amino acids, L-glutamine and PDGF-AA (30 ng ml 21 ; Peprotech)) at 37 uC with 5% CO 2 . OPCs were used between passage 10 and 15 and were never allowed to reach confluence to maintain a naive state. For differentiation, OPCs were plated in differentiation media (Neurobasal Media (Invitrogen) supplemented with B27-without vitamin A (Invitrogen), non-essential amino acids, L-glutamine and PDGF-AA (2 ng ml
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; Peprotech)). Mouse cortical neural cell mixture was prepared from E18.5 brain using the Papain dissociation system, according to the supplier's instructions kit (Worthington Biochemical). Then, both oligodendrocytes and OPCs were depleted from the mixture by sequential immunopanning as described previously 27, 52 . The cells were then cultured on poly-D-lysine-coated 8-well chamber slide (Nunc) as described previously 53 . Mouse neural stem cells (Invitrogen) were cultured in OPC medium as described previously 54 . Induced mouse OPCs (5,000 cells per well) were cultured with benztropine on the cortex-derived culture for 7 days. Cells were immunolabelled as described previously 51 . High-throughput screening and imaging. OPCs were plated at a density of 1,000 cells per well on poly-D-lysine (10 mg ml
) coated 384-well plates (Greiner) in differentiation media. Compounds were added at a final concentration of 1.5 mM within 12 h after plating the cells and incubated at 37 uC with 5% CO 2 for 6 days. Cells were then fixed for 20 min with 4% formaldehyde solution and stained with mouse anti-rat MBP antibody (Millipore) in 3% BSA, 0.3% Triton X-100 with overnight incubation at 4 uC. The cells were washed and incubated with secondary antibody (goat anti-mouse Alexa Fluor488) and DAPI (Invitrogen) for 1 h at room temperature. The cells were washed and plates were sealed and imaged using an Opera confocal imaging reader (Perkin Elmer) or a Cellomics Cell Insight imaging reader (Thermo). An air 310 lens was used to capture 9 images per well at both wavelengths (488 and 365 nm), representing different locations in a single well. For image analysis, DAPI-stained nuclei and MBP-positive cell bodies were detected using an algorithm that selects for positive cell bodies and nuclei within a range of fluorescent emission values and sizes as determined by fitting parameters to positive (thyroid hormone (T3), 1 mM) and negative controls (DMSO, 0.1%). Numerical results from the analysed images were later exported for analysis in Excel (Microsoft) and Spotfire (Tibco). Data analysis. EC 50 values were obtained by fitting the data using the sigmoidal dose-response curve-fitting function (Prism; GraphPad Software). Eight or twelve different concentrations and three data points per concentration were usually used for curve fitting. Experiments were repeated 2 or more times. Compounds. Hit compounds were purchased as powders and dissolved in DMSO for in vitro studies or saline for in vivo studies. Benztropine mesylate (MP Biomedicals), mycophenolate mofetil (Selleck Chemicals), FTY720 (Cayman Chemical), carbachol (EMD Chemicals), haloperidol (Sigma), quinpirole (Sigma), interferon-b, ipratropium (Sigma), oxybutynin (Sigma), histamine (Acros Organics), scopolamine (Sigma), atropine (Sigma), histamine trifluoromethyl toluidide (HTMT; Tocris Bioscience). In vitro myelination. Mouse embryonic stem cells (ES cells) were differentiated into neurons using a previously published protocol 26 . Neurons were allowed to mature and extend axons for about one week before plating rat primary OPCs. Cells were treated with either DMSO or 1 mM T3 or 1 mM benztropine for two weeks and myelination under different conditions was quantified. For quantification, co-cultures were fixed for 15 min in 4% PFA and stained with TUJ1 (rabbit; Covance) and MBP (mouse; Millipore) antibodies. A total of 10 randomly selected regions on 2 plates per experiment were imaged. Images were imported to Imaris (Bitplane), and axon, oligodendrocyte processes were identified. Rendered channels of the processes were exported as TIFF files to be analysed further using a custom script in MATLAB (Mathworks). Myelination was identified as regions of colocalization between MBP positive oligodendrocyte processes and TUJ1 positive neurites. Cell bodies were eliminated from the analysis to reduce the error due to non-specific overlap of MBP and TUJ1 staining. Immunocytochemistry and antibodies. Immunostaining of cells was performed using standard protocols. Primary antibodies and dilutions are provided in Supplementary Table 4 . Secondary antibodies were Alexa Fluor488 or Alexa Fluor647 conjugated anti-rabbit or anti-mouse (1:500; Invitrogen). Nuclei were counterstained with DAPI. Cells were imaged using a Nikon confocal microscope with a 310 air lens. Western blot analysis. OPCs were plated in basal differentiation medium and treated for 6 days with benztropine (1.5 mM), T3 (1 mM) or DMSO. Cells were collected by scraping, pelleted and washed with ice-cold phosphate buffered saline (PBS) before lysis with PBS containing protease inhibitors (Roche), phosphatase inhibitors (Sigma), Triton X-100 and EDTA. Following incubation on ice for 20 min, lysed cells were centrifuged (16,000g, 15 min at 4 uC). Total protein was quantified using a NanoDrop and equal amounts of protein from each sample was denatured by boiling with 43 SDS sample buffer (Invitrogen) containing b-mercaptoethanol (5%). Proteins were electrophoresed using 4-20% SDS-PAGE gels (BioRad) and transferred on to a nitrocellulose membrane (BioRad). The membrane was blocked with 5% non-fat dry milk in TRIS buffered saline with Tween-20 (0.2%) and reacted with appropriate antibodies. Blots were incubated with HRP-conjugated secondary antibodies and visualized using film and Super Signal West peroxide solution (Pierce). Semi-quantitative RT-PCR analysis. Total RNA from different samples was isolated and purified using the RNeasy mini kit (Qiagen) with on-column DNase digestion according to the manufacturer's protocol. Single-stranded cDNA was synthesized from 3 mg of total RNA with the SuperScript III First-Strand Synthesis System for RT-PCR using oligo(dT) 20 primers (Invitrogen). PCRs were performed using the Phusion High Fidelity polymerase and gene-specific primers (Supplementary Table 5 ). Cycle parameters for all genes were 30 s at 94 uC, 60 s at 57 uC and 60 s at 72 uC for 25 cycles. Quantitative RT-PCR. For expression analysis of MBP, MOG, cyclin D1, cyclin D2, c-Fos and c-Jun, RNA was isolated and reverse-transcribed to complementary DNA (cDNA) as previously described. cDNA was used for qRT-PCR with genespecific Taqman probes labelled with FAM (Applied Biosystems). qRT-PCR was performed using the ABI 7900HT instrument (Applied Biosystems) with standard parameters. The amount of cDNA was optimized so that amplification of both control genes and the cDNAs of interest were in the exponential phase. Transcripts were quantitated by comparative C t method and normalized to endogenous controls, b-actin and GAPDH.
For expression analysis of other genes, RNA was isolated and reverse-transcribed to cDNA as previously described. cDNA was used for SBYR-green based qRT-PCR using gene-specific primers (Supplementary Table 5 ). Transcripts were quantitated by comparative C t method and normalized to endogenous controls, 18S, b-actin and GAPDH. Cyclic AMP HTRF assay. OPCs were plated at a density of 8,000 cells per well onto a 384-well plate and incubated at 37 uC overnight. The assay was performed using the HRTF cAMP dynamic 2 kit (CisBio Bioassays) per the manufacturer's protocol. IBMX (1 mM final concentration) was added as a cAMP stabilizer. Data acquisition was performed in the time-resolved fluorescence resonance energy transfer (FRET) mode on Envision (PerkinElmer). The ratio between the acceptor fluorescence signal (A 665 nm) and donor fluorescence signal (A 620 nm ) 3 10 4 , representing the FRET between the conjugated cAMP and the anti-cAMP antibody, was calculated and plotted on the y axis. The ratio is inversely proportional to the endogenous cAMP levels in the sample. Calcium influx assay. Effect of compound treatment on the release of Ca 21 ions from the ER was measured using the FLIPR Tetra system (Molecular Devices). Briefly, cells were treated with carbachol as an M1/M3 agonist and the compounds were assayed for M1/M3 receptor antagonism using a Ca 21 sensitive Fluo-3AM dye. EAE model. SJL/J (8-week-old female) mice were purchased from The Jackson Laboratory. Mice were immunized subcutaneously with murine proteolipid peptide (PLP 139-151 ; Peptides International) mixed 1:1 with supplemented complete Freund's adjuvant (CFA, Fisher) followed by Bordetella pertussis toxin (200 mg per mouse, Sigma) on day 0 and day 2 as described 37 . Clinical EAE was graded on a scale of 1-5 by established standard criteria as follows: score 0, no observable disease; score 1, limp tail; score 2, limp tail and partial limb weakness; score 3, one hind limb paralyzed; score 4, both hind limbs paralyzed; score 5, moribund/dead. Mice received daily i.p. injections with compounds dissolved in saline. Dosing was commenced either on the day of PLP injections defined as prophylactic regimen or at the first appearance of EAE symptoms defined as therapeutic regimen and continued until day 30.
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Immunohistochemistry and antibodies. Spinal cords were isolated from mice using standard protocols, fixed in Formalin-Zinc overnight followed by incubation in 30% sucrose at 4 uC overnight. Spinal cords were cross-sectioned into 8 pieces and embedded in Tissue-Tek OCT (Electron Microscopy Sciences). Thin sections were cut using a Leica cryostat and stained for myelin and infiltrating cells using Luxol fast blue, PAS, haematoxylin and eosin using standard protocols. For OPC and oligodendrocyte staining, sections were treated with Cirtisolve (Fisher) antigen retrieval solution, followed by incubation with primary antibodies (Supplementary Table 3 ). Secondary antibodies were Alexa Fluor488 or Alexa Fluor647-conjugated anti-rabbit or anti-mouse (1:500; Invitrogen). Nuclei were counterstained with DAPI. Cells were imaged using a Zeiss confocal microscope. Quantitative image analysis was performed using ImageJ (NIH) and ImagePro (Media Cybernetics). Numerical results from the analysed images were exported for analysis in Excel (Microsoft).
Brains from cuprizone-treated mice were isolated using standard protocols, fixed in formalin-zinc overnight, and embedded in paraffin. Sections were deparaffinized using a standard protocol and stained with Luxol fast blue (LFB) and haematoxylin and eosin as previously described. Slides were scanned using a Leica scanner. Images from at least 6 sections were collected and quantitative image analysis was performed using ImageJ (National Institutes of Health) and ImagePro (Media Cybernetics). Numerical results from the analysed images were exported for analysis in Excel (Microsoft). Electron microscopy. Mice were exsanguinated with 0.9% saline followed by perfusion fixation with 4% paraformaldehyde, 1.5% glutaraldehyde and 1 mM CaCl 2 in 0.1 M cacodylate buffer and the spinal cords were exposed and fixed in situ overnight. Following complete removal, immersion fixation continued overnight at 4 uC in cacodylate buffered 2.5% glutaraldehyde with 1 mM CaCl 2 and then sliced into individual blocks. The tissues were then buffer washed, fixed in 1% osmium tetroxide and subsequently dehydrated in graded ethanol series, transitioned in propylene oxide and embedded in EMbed 812 / Araldite (Electron Microscopy Sciences). Thick sections (1.5 mm) were cut, mounted on glass slides and stained in toluidine blue for general assessment in the light microscope. Subsequently, 70-nm thin sections were cut with a diamond knife (Diatome), mounted on copper slot grids coated with parlodion and stained with uranyl acetate and lead citrate for examination on a Philips CM100 electron microscope (FEI) at 80 kV. Images were documented using a Megaview III CCD camera (Olympus Soft Imaging Solutions). Images were analysed in Image-Pro for g-ratio measurements by manually drawing lines across 2 perpendicular diameters each for axons and axons plus myelin. Lengths of the lines (in pixels) as generated by Image-Pro were averaged across the 2 perpendicular measurements and converted to micrometres (mm) using the image scale bars. g-ratio is defined as the ratio of the diameter of a given axon and the diameter of the axon plus myelin unit. Approximately 1,000 axons and axon plus myelin units were measured for each treatment group. In vitro T-cell assay. Spleens were isolated from SJL/J, teased apart to single cell suspensions, red blood cells were lysed and remaining cells were isolated by centrifugation, resuspended in complete media and counted. The cells were then plated with soluble anti-CD28 (5 mg ml 21 ) at 2 3 10 5 cells per well on plates precoated with anti-CD3 (10 mg ml
21
). Compounds dissolved in dimethylsulphoxide (DMSO) (,0.1%) were added at 4 different dilutions (5 mM, 500 mM, 50 mM, 5 mM) and incubated at 37 uC, 5% CO 2 for 24, 48, 72 and 96 h. Cells were analysed by flow cytometry for CFSE dilution and CD25 and CD69 expression. Cells were labelled with CFSE (3 mM) in PBS supplemented with bovine serum albumin (BSA, 0.1%). Labelling was performed in the dark at 37 uC for 10 min with occasional mixing. Labelling was stopped by addition of 5 volumes of ice-cold PBS (0.1% BSA). Labelled cells were cultured for two days and analysed on a LSR II flow cytometer (Becton Dickinson). The data was analysed using the FloJo software (Tree Star). In vivo T-cell assay. SJL/J (8-week-old female) mice were injected with PLP and Pertussis toxin to induce EAE as described in the previous section. On the same day, a prophylactic dosing regimen of compounds dissolved in saline was commenced by i.p. injections. The mice were scored and dosed daily. Mice usually developed symptoms of EAE by day 9, with the peak of symptoms appearing around day 14. Mice were sacrificed on day 14 and spleens were removed. Blood was collected for sera. Spleens were teased apart to single cell suspensions, red blood cells were lysed and splenocytes were isolated by centrifugation. Cells were resuspended in complete medium defined as Dulbecco's modified eagle medium (Gibco) supplemented with 10% fetal bovine serum (Gibco) and counted. Cells were then plated at 2 3 10 5 cells per well on a 96-well plate and treated with either 20 mg ml 21 PLP peptide or 10 ng ml 21 phorbol myristate acetate (PMA) and 300 ng ml 21 ionomycin for 48 h to stimulate cytokine production. Cytokine secretion was blocked during the last 5 h by treatment with monensin. Supernatants were collected for ELISAs of IL-2, IFN-c, IL-10 and TNF-a. Cells were stained for flow cytometry using antibodies against CD4, CD8, B220 and CD44. Cells were also stained for intracellular cytokines such as IL-2, IFN-c, IL-10 and TNF-a along with anti-CD4. Flow cytometry analysis was performed on a LSR II flow cytometer (Becton Dickinson) and the data was analysed using the FloJo software (Tree Star). In vivo assays for T-cell-dependent B-cell responses. SJL/J mice were injected i.p. with TNP-KLH (Biosearch Technology; 25 mg per mouse in complete Freund's adjuvant). Benztropine (10 mg per kg) or vehicle was injected i.p. daily for 21 days. Sera were collected on day 0, 7, 14 and 21. The collected sera was analysed by ELISA for anti-TNP IgG levels. Bone marrow-derived macrophages and M1/M2 polarization. Bone marrowderived macrophage (BMM) cultures were generated from adult SJL/J mice. Briefly, femurs and tibias were collected bilaterally and marrow cores were flushed using syringes filled with DMEM medium supplemented by with 1% penicillin/streptomycin, 1% HEPES, 1% sodium pyruvate, 0.1% b-mercaptoethanol and 10% FBS (complete DMEM) (Gibco). Cells suspension were filtered through a 0.2 mm cell strainer, counted, plated in complete DMEM supplemented with 5% of horse serum and 20% supernatant from macrophage colony stimulating factor secreting L929 (sL929) cells. The sL929 drives bone marrow cells towards a macrophage phenotype (10 days). Non-adherent cells were removed at day 4. At collection (day 10), 90 6 0.7% of cells were macrophages (assessed by F4/80 immunostaining). To promote differentiation into M1 or M2 macrophages, cells were treated with LPS (100 ng ml
; Sigma-Aldrich) plus IFNc (20 ng ml
; Peprotech) or IL-4 plus IL-13 (20 ng ml
; Peprotech), respectively, for 16 h, in the presence or absence of benztropine (5 mM). After M1 or M2 polarization, some cells (cultured without benztropine) were saved and treated once again, as described above. The viability of M1/M2 macrophages was analysed in every experiment by flow cytometry of DAPI-stained cells (Invitrogen). Supernatants and cells were subsequently collected for cytokine (TNF-a) and phenotypic analysis, respectively. M1 and M2 polarization was assessed using the following fluorochrome-labelled antibodies: anti-F4/80, rat anti-mouse mannose receptor (CD206), rat anti-mouse CD86, rat anti-mouse CD80 and anti-mouse I-A/I-E antibodies (BioLegend). Isolation of spleen and leukocyte isolation from spinal cords. EAE mice were euthanized, spleens were isolated from the mice as per standard protocols and crushed by mechanical disruption using a tissue homogenizer. Spinal cords were isolated from the mice, treated with collagenase and ground to a single cell suspension. Suspensions from 2 spinal cords from mice with similar clinical severity scores were combined and centrifuged through gradients of 30% and 70% Percoll to isolate infiltrating leukocytes. Total RNA was isolated and used for gene expression analysis as previously described. Adoptive transfer EAE. SJL/J donor mice were purchased from The Jackson Laboratories. Mice were immunized subcutaneously with murine proteolipid peptide (PLP 139-151 ; Peptides International) mixed 1:1 with supplemented complete Freund's adjuvant (CFA, Fisher). Mice were then either injected with saline or benztropine (10 mg per kg, daily, i.p.) for 7 days, and re-immunized with murine PLP emulsified 1:1 with incomplete Freund's adjuvant. Daily benztropine or vehicle injections were continued until day 10, when spleens were isolated, teased apart to single cell suspensions, red blood cells lysed and splenocytes isolated by centrifugation. Cells were resuspended in complete media (RPMI 1640 supplemented with 10% fetal bovine serum (FBS), 1.25% HEPES buffer, 1% sodium pyruvate, 1% penicillin-strepyomycin, 1% glutamine, 1% non-essential amino acids, 0.01% 2-mercaptoethanol (2-ME)) (Sigma-Aldrich) and counted. Splenocytes were analysed by flow cytometry to determine cell viability and percentage of CD4 1 T cells as described earlier. Splenocytes from vehicle-treated mice were further cultured in vitro in the presence of PLP 139-151 (30 mg ml 21 ), interleukin 12 (IL-12) (10 ng ml
) and DMSO (,0.1%), whereas splenocytes from benztropinetreated donor mice were further cultured in vitro in the presence of PLP 139-151 , interlukin 12 (IL-12) (10 ng ml
) and benztropine (5 mM) for 72 h at 37 uC. At the end of 72 h, cells were analysed by flow cytometry to determine cell viability and percentage of CD4 1 T cells as described earlier (,80% activated T cells after in vitro culture). Cells were then washed and resuspended in PBS (50 million cells ml
) and 200 ml of cell suspension was injected into 4 groups (according to the following table) of naive recipient SJL/J mice by intravenous injection followed by Bordetella pertussis toxin (i.p., 200 mg per mouse, Sigma) on day 0 and day 2. Clinical EAE was graded on a scale of 1-5 by established standard criteria as follows: score 0, no observable disease; score 1, limp tail; score 2, limp tail and partial limb weakness; score 3, one hind limb paralyzed; score 4, both hind limbs paralyzed; score 5, moribund/dead. Mice received daily i.p. injections of either saline or benztropine (10 mg per kg) according to Extended Data Fig. 8c, d . Cuprizone model. C57BL/6 mice (8-week-old females) were purchased from the breeding colony at The Scripps Research Institute. Mice were fed 0.2% w/w cuprizone (bis-cyclohexanone oxaldihydrazone, Sigma-Aldrich) mixed into a ground standard rodent chow (Harlan). Cuprizone diet was maintained for 7 weeks; thereafter mice were put on a normal chow for another 5 weeks. Compounds were RESEARCH ARTICLE dissolved in saline and daily i.p. injections were initiated at the withdrawal of the cuprizone diet. At different time points (0, 1, 2, 3, 4 and 5 weeks after cuprizone withdrawal), animals were euthanized. Brains were extracted, fixed in formalinzinc, paraffin-embedded, sectioned and stained as described in the immunohistochemistry section. Image analysis of brain sections. Using ImageJ (NIH), images were converted to a 256-shade grey scale. The 256 shades of grey were then divided into 5 bins of 50 shades each: 0-50, 50-100, 100-150, 150-200 and 200-256, with 0 being the pixel with darkest shade of grey and 256 being the pixel with the lightest shade of grey. Each bin was assigned an arbitrary colour: 0-50 (red), 50-100 (yellow), 100-150 (green), 150-200 (light blue) and 200-256 (dark blue). Based on the intensity of staining, each pixel was classified into one of the 5 bins using Image-Pro plus software. The number of objects in the corpus callosum region classified into each bin was counted. Data was exported to Excel (Microsoft) for analysis. s.e.m., **P , 0.01, t-test). Scale bars, 100 mm. e, EAE mice treated with benztropine (10 mg per kg) or vehicle in prophylactic mode and spinal cord sections from mice representative of the average group scores on day 11 and 14, immunostained with antibody specific to MBP. Arrows point to regions of lymphocyte infiltration. Scale bars, 100 mm. f, Electron microscopy images showing myelin around axons in normal mice, vehicle-treated mice and mice in remission. Scale bars as indicated. g, Analysis of electron microscopy images indicating distribution of axonal diameters measured for 4 groups. h, Analysis of electron microscopy images indicating distribution of g-ratios of axons for 4 groups. i, Scatterplot of g-ratios in relation to spinal cord axonal diameters (n 5 1,000, ***P , 0.001, one-way ANOVA, exponential trend line). j, Quantification of the number of axons associated with oligodendrocytes (n 5 25, mean and s.e.m., **P , 0.01, t-test). Oligodendrocytes were identified visually by their cytoplasmic processes wrapping around axons.
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Extended Data Figure 5 | Benztropine has no effect on in vitro and in vivo immunological responses in EAE mice. a, Benztropine and various muscarinic antagonists have no effect on in vitro T-cell proliferation measured using carboxyfluorescein succinimidyl ester (CFSE) labelling, whereas mycophenolate and FTY720 suppress T-cell proliferation as determined by the percentage of CD4 1 T-cell-gated populations positive for the given marker. b, c, Various muscarinic antagonists have no effect on T-cell activation as measured by CD4 , and CD44 Hi cells in spleens isolated from vehicle-and benztropine-treated mice. e, f, Total splenocytes isolated from benztropine (10 mg per kg) or vehicle treated (14 days in the prophylactic mode) naive SJL/J (e) or EAE (f) mice analysed for various populations of immune cells and cytokine secretion. Benztropine treatment had no effect on the numbers of total splenocytes, CD4
1 T cells, CD8 1 T cells, CD4
1
CD44
Hi T cells and CD8
1
CD44
Hi T cells. Benztropine treatment showed a minor, but significant decrease in the number of B cells (n 5 5, mean and s.e.m., *P , 0.05, t-test). Benztropine had no effect on cytokine production from CD4 1 T cells expressing IL-2, IL-10, TNF-a or IFN-c. (n 5 5, mean and s.e.m.). g, Benztropine showed no effect on keyhole limpet hemocyanin protein conjugated to 2,4,6-trinitrophenyl hapten (TNP-KLH)-induced T-celldependent B-cell response. Mice were injected with TNP-KLH in adjuvant and treated with vehicle or benztropine (10 mg per kg) daily. Serum was isolated at various time points and anti-TNP-IgG levels were measured by ELISA. (3 replicate ELISAs, n 5 5 mice per group, mean and s.e.m.).
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